Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02KNW
|
|||
| Drug Name |
PMID25656651-Compound-36a
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
NOVARTIS AG FURET, Pascal GROTZFELD, Robert Martin JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas MOUSSAOUI, Saliha PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph JAHNKE, Wolfgang
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H12ClF2N3O2
|
|||
| Canonical SMILES |
C1=CC(=CC(=C1)C(=O)NC2=CC=C(C=C2)OC(F)(F)Cl)C3=CN=CN=C3
|
|||
| InChI |
1S/C18H12ClF2N3O2/c19-18(20,21)26-16-6-4-15(5-7-16)24-17(25)13-3-1-2-12(8-13)14-9-22-11-23-10-14/h1-11H,(H,24,25)
|
|||
| InChIKey |
IEPKEELESQZYDU-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [1] |
| Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Fusion protein Bcr-Abl (Bcr-Abl) | Target's Patent Info | [1] | |
| Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target's Patent Info | [1] | ||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.